MindMed Archives

Psychedelics News

MindMed

Breaking News, Industry

11 May 2022

Breaking News: MindMed Announces Positive Results from Phase 2 LSD Trial

Microdose was at the event and the anticipation for MindMed's results was palpable....

By Microdose NewsDesk

Finance

6 May 2022

MindMed Receives 700% Price Target From Roth Capital

Roth Capital Partners has initiated coverage on MindMed with a $7 price target, over 700% the current stock price....

By Jason Najum

Finance

5 May 2022

MindMed Files For $200 Million Raise

MindMed has quietly filed a prospectus with the SEC for a "mixed shelf" offering with proceeds of up to $200 million...

By Jason Najum

Industry

14 Apr 2022

MindMed to Announce Results for LSD Trial

Today we learned that MindMed collaborators from the University Hospital Basel will present results from their Phase 2 clinical trial of LSD in the treatment of anxiety disorders....

By Jason Najum

Join Our Newsletter for Exclusive Updates, Stories, and More

Industry

16 Mar 2022

Novamind to Host MindMed’s Phase 2b Trial

Novamind will host the LSD Clinical Trial at its Draper, Utah research site, further strengthening its track record of hosting neuropsychiatry and psychedelic clinical trials....

By Microdose

Industry

2 Mar 2022

MindMed Announces Study Comparing LSD and Psilocybin

Back in the spring of 2020, in the early days of the psychedelic medicine industry, MindMed signed one of the sector's most significant research collaborations....

By Jason Najum

Breaking News

25 Jan 2022

Breaking News: FDA Clears MindMed’s Phase 2b LSD Trial

FDA clearance leads to first commercial IND for LSD, enabling MinfdMed to start Phase 2b dose-optimization trial in early 2022...

By Jason Najum

Industry

4 Jan 2022

MindMed Successfully Completes Phase 1 Trial of 18-MC

18-MC is MindMed's non-hallucinogenic proprietary derivative of ibogaine, being developed for the treatment of indications linked to opioid use disorder....

By Jason Najum

Industry

22 Dec 2021

MindMed Provides Update on Phase 2b LSD Trial

It’s been a rough 6 months for most of the psychedelic medicine industry....

By Jason Najum

Follow us on social

Latest News

AbbVie Withdraws Patent Challenge, Clearing Path for Enveric’s Psychedelic IP Strategy

Breaking: Enveric Reports New Mechanistic Data Supporting Non-Hallucinogenic Neuroplastogen Strategy

Two New Studies Are Rewriting the Rules of Psychedelic Drug Development

Professional Training in Psychedelic Medicine

Psychedelic medicine is reshaping the future of mental health care. From the power of microdosing LSD to the promise of MDMA in PTSD, the world of medical psychedelics offers transformative possibilities. Our comprehensive, CE-accredited course provides you with the knowledge and understanding you need to tap into this groundbreaking field.

WordPress Ads

No Result

View All Result